BTXA-51 is under clinical development by BioTheryX and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BTXA-51’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BTXA-51 is under development for the treatment of relapsed or refractory acute myeloid leukemia, high risk myelodysplastic syndrome, metastatic solid tumor and B-cell non-Hodgkin lymphoma. It is administered by oral route. The drug candidate is a multi-kinase inhibitor that acts by targeting casein kinase I alpha (CKI-alpha) as well as super enhancer targets (CDK7/CDK9).
BioTheryX is a clinical-stage biopharmaceutical company focusing on restoring protein homeostasis, including protein degradation and modulation, multi-kinase inhibition to develop treatments intended to improve and extend the quality-of-life of patients with life-threatening diseases. BioTheryX is headquartered in San Diego, California, the US.
For a complete picture of BTXA-51’s drug-specific PTSR and LoA scores, buy the report here.